AEON Biopharma (NASDAQ:AEON – Get Free Report) and MindWalk (NASDAQ:HYFT – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.
Institutional and Insider Ownership
22.8% of AEON Biopharma shares are held by institutional investors. Comparatively, 6.7% of MindWalk shares are held by institutional investors. 0.9% of AEON Biopharma shares are held by insiders. Comparatively, 6.8% of MindWalk shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Risk & Volatility
AEON Biopharma has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, MindWalk has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| AEON Biopharma | N/A | N/A | -994.63% |
| MindWalk | -145.58% | -56.75% | -31.55% |
Earnings & Valuation
This table compares AEON Biopharma and MindWalk”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AEON Biopharma | N/A | N/A | -$36.63 million | $5.04 | 0.22 |
| MindWalk | $17.59 million | 3.12 | -$21.69 million | ($0.60) | -1.98 |
MindWalk has higher revenue and earnings than AEON Biopharma. MindWalk is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings for AEON Biopharma and MindWalk, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AEON Biopharma | 0 | 1 | 1 | 1 | 3.00 |
| MindWalk | 1 | 1 | 0 | 0 | 1.50 |
Summary
AEON Biopharma beats MindWalk on 9 of the 13 factors compared between the two stocks.
About AEON Biopharma
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.
About MindWalk
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.
Receive News & Ratings for AEON Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEON Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
